Medical Treatment of Aortic Aneurysms in Marfan Syndrome and Other Heritable Conditions

ISSN: 1875-6557 (Online)
ISSN: 1573-403X (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Cardiology Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Fei Lu
University of Minnesota Medical School
Minneapolis, MN 55455
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Medical Treatment of Aortic Aneurysms in Marfan Syndrome and Other Heritable Conditions

Author(s): Christine H. Attenhofer Jost, Matthias Greutmann, Heidi M. Connolly, Roland Weber, Marianne Rohrbach, Angela Oxenius, Oliver Kretschmar, Thomas F. Luscher and Gabor Matyas

Affiliation: Cardiovascular Center Zurich, Klinik Im Park Seestr. 220 CH-8027 Zurich Switzerland

Abstract

Thoracic aortic aneurysms can be triggered by genetic disorders such as Marfan syndrome (MFS) and related aortic diseases as well as by inflammatory disorders such as giant cell arteritis or atherosclerosis. In all these conditions, cardiovascular risk factors, such as systemic arterial hypertension, may contribute to faster rate of aneurysm progression. Optimal medical management to prevent progressive aortic dilatation and aortic dissection is unknown. β-blockers have been the mainstay of medical treatment for many years despite limited evidence of beneficial effects. Recently, losartan, an angiotensin II type I receptor antagonist (ARB), has shown promising results in a mouse model of MFS and subsequently in humans with MFS and hence is increasingly used. Several ongoing trials comparing losartan to β-blockers and/or placebo will better define the role of ARBs in the near future. In addition, other medications, such as statins and tetracyclines have demonstrated potential benefit in experimental aortic aneurysm studies. Given the advances in our understanding of molecular mechanisms triggering aortic dilatation and dissection, individualized management tailored to the underlying genetic defect may be on the horizon of individualized medicine. We anticipate that ongoing research will address the question whether such genotype/pathogenesis-driven treatments can replace current phenotype/syndrome-driven strategies and whether other forms of aortopathies should be treated similarly. In this work, we review currently used and promising medical treatment options for patients with heritable aortic aneurysmal disorders

Keywords: Angiotensin II receptor antagonists, aortic aneurysm, beta-blockers, genetics, Marfan syndrome, medical management, risk factors, statins

Download Free Rights and Permissions

Article Details

Volume: 10
First Page: 1
Last Page: 11
Page Count: 11
DOI: 10.2174/1573403X10666140214123438
Advertisement

Related Journals



Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science